Bank of America Securities: Raising Target Price of MicroPort Medical (00853.HK) to HK$17, Reiterating "Buy" Rating

According to the Zhicaitong Finance and Economics app, Bank of America Securities released a research report stating that it reaffirmed its "buy" rating on MicroPort Medical (00853.HK) because of its attractive risk-return profile. The company has a diversified portfolio of high-value medical consumables, with its robotic surgery business expected to be a key driver of future growth. The bank expects robotic surgery to contribute 19% of total revenue by 2034. Additionally, the bank believes that MicroPort Medical's shareholder, Shanghai Fosun Pharmaceutical Group, may provide financial and operational support, and will work on the company's governance structure. The company is also addressing liquidity concerns, and through cost control and disposal of non-core assets, it is expected to achieve profitability from the first half of 2026. The bank has raised its total revenue forecast for 2026 to 2034 by 0.1% to 1.5% and increased its target price from HK$16.8 to HK$17.